Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC).

被引：0
|
作者：
Goh, Jeffrey [1 ]
Coward, Jermaine [1 ]
Gao, Bo [2 ]
da Silva, Ines P. [3 ,4 ]
Voskoboynik, Mark [5 ,6 ]
Day, Daphne [7 ,8 ]
Body, Amy L. [7 ,8 ]
Gan, Hui K. [9 ]
Chen, Cheng [10 ]
Xiang, Xiao [10 ]
Fei, Cong [10 ]
Yang, Liu [10 ]
Millward, Michael [11 ,12 ]
机构：
[1] Icon Canc Ctr, Brisbane, Qld, Australia
[2] Blacktown Canc & Haematol Ctr, Blacktown, NSW, Australia
[3] Blacktown Hosp, Sydney, NSW, Australia
[4] Westmead Hosp, Sydney, NSW, Australia
[5] Nucleus Network, Melbourne, Vic, Australia
[6] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia
[7] Monash Hlth, Melbourne, Vic, Australia
[8] Monash Univ, Melbourne, Vic, Australia
[9] Austin Hlth, Heidelberg, Vic, Australia
[10] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[11] Linear Clin Res, Nedlands, WA, Australia
[12] Univ Western Australia, Nedlands, WA, Australia
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT013
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
    Goh, J. C.
    Coward, J.
    Gao, B.
    Da Silva, I. Pires
    Voskoboynik, M.
    Day, D.
    Body, A.
    Gan, H. K.
    Li, X.
    Sun, J.
    Fei, C.
    Yang, L.
    Millward, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1446 - S1447
  • [2] Safety/tolerability and preliminary antitumour activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
    Goh, Jeff
    Coward, Jermaine
    Gao, Bo
    da Silva, Ines Pires
    Voskoboynik, Mark
    Day, Daphne
    Body, Amy Louise
    Gan, Hui K.
    Chen, Cheng
    Xiang, Xiao
    Fei, Cong
    Yang, Liu
    Millward, Michael
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 65 - 65
  • [3] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
    Zhang, Feng
    Bai, Yuxian
    Fang, Weijia
    Meng, Zhiqiang
    Xiong, Jianping
    Guo, Yabing
    Zhang, Tao
    Zhang, Jingdong
    Ying, Jieer
    Chen, Zhendong
    Ren, Zhenggang
    Chen, Yajin
    Hao, Chunyi
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Wu, Xikun
    Qin, Shukui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [4] The safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with locally recurrent or metastatic triple-negative breast cancer.
    Fan, Lei
    Liu, Xiyu
    Jin, Xi
    Yang, Yunsong
    Chen, Li
    Hu, Xin
    Wang, Zhonghua
    Jiang, Yizhou
    Shao, Zhimin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data
    Gao, B.
    Goh, J.
    Markman, B.
    Voskoboynik, M.
    Gan, H. K.
    Coward, J.
    Palmieri, D.
    So, J.
    Meniawy, T.
    Chen, C.
    Xiang, X.
    Qiu, J.
    Xu, Y.
    Yang, L.
    Millward, M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [6] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
    Chen, Zhendong
    Bai, Yuxian
    Zhang, Tao
    Ying, Jieer
    Lin, Xiaoyan
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Huang, Ruiqi
    Li, Jin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors
    Goh, Jeffrey
    Gao, Ben
    Markman, Ben
    Gan, Hui
    Voskoboynik, Mark
    Wu, Yi-Long
    Guo, Jun
    Zhou, Qing
    Zhao, Jun
    Chen, Cheng
    Qiu, Jingjun
    Xu, Yingying
    Yang, Liu
    Millward, Michael
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [8] Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab
    Konstantinopoulos, P. A.
    Munster, P.
    Forero-Torez, A.
    Holloway, R. W.
    Schwartzberg, L.
    Matulonis, U. A.
    Wang, J.
    Guo, W.
    Dezube, B.
    Vinayak, S.
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 149 : 246 - 246
  • [9] Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
    Hamanishi, Junzo
    Mandai, Masaki
    Ikeda, Takafumi
    Minami, Manabu
    Kawaguchi, Atsushi
    Murayama, Toshinori
    Kanai, Masashi
    Mori, Yukiko
    Matsumoto, Shigemi
    Chikuma, Shunsuke
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Yamaguchi, Ken
    Ueda, Akihiko
    Hosoe, Yuko
    Morita, Satoshi
    Yokode, Masayuki
    Shimizu, Akira
    Honjo, Tasuku
    Konishi, Ikuo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4015 - +
  • [10] Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study.
    Cui, Chuanliang
    Pan, Hongming
    Carlino, Matteo
    Cui, Jiuwei
    Wang, Xuan
    Chen, Cheng
    Xiang, Xiao
    Yang, Liu
    Guo, Jun
    [J]. CANCER RESEARCH, 2021, 81 (13)
12345